A Phase 2 interventional study of Antidepressant + placebo and Antidepressant + cariprazine (0.1-0.3 mg/day) in Major Depressive Disorder, sponsored by Forest Laboratories. Completed at 41 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-03-05.
Sponsored by Forest Laboratories (part of AbbVie) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Depressive Disorder, Major by AbbVie — 1 open to participants now, 1 under way, none of them phase 3. Depressive Disorder, Major · AbbVie.
Among the 53 studies in Depressive Disorder, Major by AbbVie, this one is the 38th largest by enrollment, is one of 5 that started in 2009, is one of 12 in phase 2, and was the 8th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 53 studies in Depressive Disorder, Major by AbbVie is open now, in 1 country. Recruiting first, the newest first:
AbbVie · Sites in United States
Ages 18–65
By country, each count listing its studies:
Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 5 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 231 is above the median of 79 across 2,533 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 442 across the 53 interventional studies. Of the 50 that completed or were terminated, 37 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Forest Laboratories, one of the names counted as AbbVie. Under that name alone:
Forest Laboratories is the lead sponsor of 168 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
1 of the studies in Depressive Disorder, Major by AbbVie that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07276997AbbVieA Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 53 studies in Depressive Disorder, Major by AbbVie, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an outpatient study to evaluate the safety, and efficacy of RGH-188 as an add-on therapy to standard antidepressants in patients who did not respond to previous antidepressant therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + Placebo
Drug: Antidepressant + placebo
Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR)+ cariprazine low dose
Drug: Antidepressant + cariprazine (0.1-0.3 mg/day)
Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + cariprazine high dose
Drug: Antidepressant + cariprazine (1-2 mg/d)
Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + Placebo Oral, once daily for 8 weeks following an 8 week Prospective Treatment (Baseline) Period.
Drug page: Cariprazine
Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + cariprazine (0.1-0.3 mg/d) Oral, once daily for 8 weeks following an 8 week Prospective Treatment (Baseline) Period.
Drug page: Cariprazine
Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + cariprazine (1-2 mg/d) Oral, once daily for 8 weeks following an 8 week Prospective Treatment (Baseline) Period.
Montgomery-Asberg Depression Rating Scale (MADRS)
The patient is rated on a scale from 0-6 on 10 items. Apparent sadness, reported sadness, lassitude, pessimistic thoughts, inner tension, suicidal thoughts, reduced sleep and appetite, concentration difficulties, inability to feel. The overall MADRS score ranges from 0-60, with 0 meaning no symptoms and score of 60 meaning maximum severity. The primary efficacy parameter was the change in MADRS score totals from the scores taken at Baseline (Week 8) and during at least one more time point up to and including Week 16.
Time frame: Baseline (Week 8) to Week 16
Clinical Global Impression - Improvement (CGI-I)
The Clinical Global Impression-Improvement (CGI-I) scale is a clinician rated scale that, in this study, will be used to rate total improvement or worsening of mental illness starting at Visit 2 (Week 2) and taken at every visit through Visit 11 (Week 16). The patient will be rated on a scale from 1 to 7, 1 indicating that the patient is very much improved and 7 indicating that the patient is very much worse. The secondary efficacy parameter was the CGI-I total score at Week 16.
Time frame: Week 16
| Milestone | Placebo | Cariprazine 0.1 - 0.3 mg | Cariprazine 1.0 - 2.0 mg |
|---|---|---|---|
| Started | 81 | 76 | 74 |
| Completed | 72 | 70 | 63 |
| Not completed | 9 | 6 | 11 |
| Withdrew: Inability to complete the study visits | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 2 | 0 | 3 |
| Withdrew: Withdrawal by subject | 3 | 1 | 2 |
| Withdrew: Protocol violation | 2 | 4 | 3 |
| Withdrew: Adverse event | 2 | 1 | 2 |
The patient is rated on a scale from 0-6 on 10 items. Apparent sadness, reported sadness, lassitude, pessimistic thoughts, inner tension, suicidal thoughts, reduced sleep and appetite, concentration difficulties, inability to feel. The overall MADRS score ranges from 0-60, with 0 meaning no symptoms and score of 60 meaning maximum severity. The primary efficacy parameter was the change in MADRS score totals from the scores taken at Baseline (Week 8) and during at least one more time point up to and including Week 16.
| Units on a Scale | Placebo | Cariprazine 0.1 - 0.3 mg | Cariprazine 1.0 - 2.0 mg |
|---|---|---|---|
| Montgomery-Asberg Depression Rating Scale (MADRS) | -8.0 ± 1.0 | -7.5 ± 1.1 | -9.8 ± 1.1 |
The Clinical Global Impression-Improvement (CGI-I) scale is a clinician rated scale that, in this study, will be used to rate total improvement or worsening of mental illness starting at Visit 2 (Week 2) and taken at every visit through Visit 11 (Week 16). The patient will be rated on a scale from 1 to 7, 1 indicating that the patient is very much improved and 7 indicating that the patient is very much worse. The secondary efficacy parameter was the CGI-I total score at Week 16.
| Units on a Scale | Placebo | Cariprazine 0.1 - 0.3 mg | Cariprazine 1.0 - 2.0 mg |
|---|---|---|---|
| Clinical Global Impression - Improvement (CGI-I) | 2.5 ± 0.1 | 2.5 ± 0.1 | 2.3 ± 0.1 |
Collected over Up to 20 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Prospective Antidepressant-Therapy Lead In Period | 1/502 (0.2%) | 9/502 (1.8%) | 262/502 (52.2%) |
| Placebo | 0/81 (0%) | 1/81 (1.2%) | 32/81 (39.5%) |
| Cariprazine 0.1 - 0.3 mg | 0/76 (0%) | 0/76 (0%) | 29/76 (38.2%) |
| Cariprazine 1.0 - 2.0 mg | 0/73 (0%) | 1/73 (1.4%) | 35/73 (47.9%) |
| Event | Prospective Antidepressant-Therapy Lead In Period | Placebo | Cariprazine 0.1 - 0.3 mg | Cariprazine 1.0 - 2.0 mg |
|---|---|---|---|---|
| Chronic Obstructive Pulmanary DiseaseRespiratory, thoracic and mediastinal disorders | 0/502 | 0/81 | 0/76 | 1/73 |
| Angina UnstableCardiac disorders | 0/502 | 1/81 | 0/76 | 0/73 |
| Suicidal IdeationPsychiatric disorders | 2/502 | 0/81 | 0/76 | 0/73 |
| AnxietyPsychiatric disorders | 1/502 | 0/81 | 0/76 | 0/73 |
| Hip FractureInjury, poisoning and procedural complications | 1/502 | 0/81 | 0/76 | 0/73 |
| Road Traffic AccidentInjury, poisoning and procedural complications | 1/502 | 0/81 | 0/76 | 0/73 |
| Upper Limb FractureInjury, poisoning and procedural complications | 1/502 | 0/81 | 0/76 | 0/73 |
| DepressionPsychiatric disorders | 1/502 | 0/81 | 0/76 | 0/73 |
| ConvulsionNervous system disorders | 1/502 | 0/81 | 0/76 | 0/73 |
| Serotonin SyndromeNervous system disorders | 1/502 | 0/81 | 0/76 | 0/73 |
| Event | Prospective Antidepressant-Therapy Lead In Period | Placebo | Cariprazine 0.1 - 0.3 mg | Cariprazine 1.0 - 2.0 mg |
|---|---|---|---|---|
| HeadacheNervous system disorders | 73/502 | 3/81 | 8/76 | 6/73 |
| NauseaGastrointestinal disorders | 70/502 | 5/81 | 5/76 | 5/73 |
| InsomniaPsychiatric disorders | 60/502 | 3/81 | 2/76 | 7/73 |
| Dry MouthGastrointestinal disorders | 53/502 | 1/81 | 2/76 | 4/73 |
| RestlessnessPsychiatric disorders | 0/502 | 1/81 | 1/76 | 7/73 |
| DizzinessNervous system disorders | 31/502 | 7/81 | 4/76 | 6/73 |
| NasopharyngitisInfections and infestations | 0/502 | 5/81 | 1/76 | 6/73 |
| FatigueGeneral disorders | 36/502 | 3/81 | 2/76 | 5/73 |
| DiarrhoeaGastrointestinal disorders | 36/502 | 5/81 | 4/76 | 3/73 |
| ConstipationGastrointestinal disorders | 35/502 | 1/81 | 1/76 | 4/73 |
A total of 231 patients were eligible for randomization to double-blind treatment; 230 patients were randomized and received at least 1 dose of treatment (Double-blind Safety Population)
| Age, Continuous(Years) | Placebo | Cariprazine 0.1 - 0.3 mg | Cariprazine 1.0 - 2.0 mg | Total |
|---|---|---|---|---|
| Mean | 45.2 ± 10.2 | 46.6 ± 11.7 | 44.2 ± 12.1 | 45.3 ± 11.3 |
| Sex: Female, Male(Participants) | Placebo | Cariprazine 0.1 - 0.3 mg | Cariprazine 1.0 - 2.0 mg | Total |
|---|---|---|---|---|
| Female | 61 | 52 | 51 | 164 |
| Male | 20 | 24 | 22 | 66 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Cariprazine 0.1 - 0.3 mg | Cariprazine 1.0 - 2.0 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 7 | 9 | 9 | 25 |
| Not Hispanic or Latino | 74 | 67 | 64 | 205 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | Cariprazine 0.1 - 0.3 mg | Cariprazine 1.0 - 2.0 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 0 | 0 | 2 |
| Asian | 0 | 2 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 10 | 15 | 11 | 36 |
| White | 69 | 57 | 60 | 186 |
| More than one race | 0 | 2 | 1 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
Ran from Jun 2009 to primary completion in Dec 2010, 17 months.
Results were first posted in Mar 2019, 8 years 2 months after primary completion. A results delay was requested in Feb 2012.
Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 17 months is close to that.
Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cariprazine